Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Neha Panjwani

What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock?

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $109.2 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases.

Shares of the biotechnology company have underperformed the broader market over the past year. VRTX has declined 3.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 25.1%. In 2026, VRTX’s stock fell 5.1%, compared to the SPX’s 8.6% rise on a YTD basis.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.